Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770662 | 0.91 | FAAH (0.54) | FAAHTRPV1SMN1; SMN2 | |
| SCHEMBL3767408 | 0.89 | FAAH (0.55) | FAAHTRPV1NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3767493 | 0.87 | FAAH (0.54) | FAAHNPC1SMN1; SMN2 | |
| SCHEMBL3769724 | 0.83 | FAAH (0.73) | FAAHNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27004159 | 0.81 | FAAH (0.63) | FAAHTRPV1NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3771978 | 0.79 | FAAH (1.00) | FAAHTRPV1CNR2NPC1ALDH1A1 | |
| SCHEMBL3268330 | 0.79 | FAAH (0.52) | FAAHTRPV1ALDH1A1 | |
| SCHEMBL18711879 | 0.77 | FAAH (0.59) | FAAHSPRALDH1A1SMN1; SMN2 | |
| SCHEMBL3770648 | 0.77 | HDAC3 (0.48) | — | |
| SCHEMBL19358925 | 0.77 | FAAH (0.60) | FAAHTRPV1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | claimed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | claimed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885TRPV1 87/4885CNR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.